Amgen 4Q Revenues: $5.8 billion (-3%) 4Q Loss: $4.3 billion (earnings were $1.9 billion 4Q16) FY Revenues: $22.8 billion (-1%) FY Earnings: $2.0 billion (-74%) Comments: Enbrel sales were down 13% to $1.4 billion due to lower unit demand and net selling price. Neulasta sales were flat in the quarter at $1.1 billion with lower unit demand offset by favorable changes in accounting estimates. Repatha sales increased 69% to $98 million in the quarter driven by higher demand. BLINCYTO sales incr...